Cargando…

A novel approach in the treatment of neuroendocrine gastrointestinal tumors: Additive antiproliferative effects of interferon-γ and meta-iodobenzylguanidine

BACKGROUND: Therapeutic options to effectively inhibit growth and spread of neuroendocrine gastrointestinal tumors are still limited. As both meta-iodobenzylguanidine (MIBG) and interferon-γ (IFNγ) cause antineoplastic effects in neuroendocrine gastrointestinal tumor cells, we investigated the antip...

Descripción completa

Detalles Bibliográficos
Autores principales:	Höpfner, Michael, Sutter, Andreas P, Huether, Alexander, Ahnert-Hilger, Gudrun, Scherübl, Hans
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2004
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC442128/ https://www.ncbi.nlm.nih.gov/pubmed/15154969 http://dx.doi.org/10.1186/1471-2407-4-23

Ejemplares similares

A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839)
por: Höpfner, M, et al.
Publicado: (2003)

Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters
por: Kölby, L, et al.
Publicado: (2003)

Modification of meta-iodobenzylguanidine uptake in neuroblastoma cells by elevated temperature.
por: Armour, A., et al.
Publicado: (1994)

A convenient Simple Method for Synthesis of Meta-iodobenzylguanidine (MIBG)
por: Sheikholislam, Zahra, et al.
Publicado: (2013)

131I-meta-iodobenzylguanidine therapy in neuroblastoma spheroids of different sizes.
por: Gaze, M. N., et al.
Publicado: (1992)

(123)I-Meta-iodobenzylguanidine Sympathetic Imaging: Standardization and Application to Neurological Diseases
por: Nakajima, Kenichi, et al.
Publicado: (2016)

A model of modified meta-iodobenzylguanidine conjugated gold nanoparticles for neuroblastoma treatment
por: Saimuang, Kween, et al.
Publicado: (2021)

Bioavailability and toxicity after oral administration of m-iodobenzylguanidine (MIBG)
por: Kuin, A, et al.
Publicado: (1999)

Additively Enhanced Antiproliferative Effect of Interferon Combined with Proanthocyanidin on Bladder Cancer Cells
por: Fishman, Andrew I., et al.
Publicado: (2012)

Radiosynthesis of no-carrier-added meta-[(124)I]iodobenzylguanidine for PET imaging of metastatic neuroblastoma
por: Green, Michael, et al.
Publicado: (2016)

Biomarker response to high-specific-activity I-131 meta-iodobenzylguanidine in pheochromocytoma/paraganglioma
por: Jimenez, Camilo, et al.
Publicado: (2022)

Reproducibility of planar (123)I-meta-iodobenzylguanidine (MIBG) myocardial scintigraphy in patients with heart failure
por: Veltman, Caroline E., et al.
Publicado: (2012)

Standardization of (123)I-meta-iodobenzylguanidine myocardial sympathetic activity imaging: phantom calibration and clinical applications
por: Nakajima, Kenichi, et al.
Publicado: (2017)

Diagnostic Accuracy of (123)I-Meta-Iodobenzylguanidine Myocardial Scintigraphy in Dementia with Lewy Bodies: A Multicenter Study
por: Yoshita, Mitsuhiro, et al.
Publicado: (2015)

Cross calibration of (123)I-meta-iodobenzylguanidine heart-to-mediastinum ratio with D-SPECT planogram and Anger camera
por: Nakajima, Kenichi, et al.
Publicado: (2017)

A phase I clinical trial for [(131)I]meta-iodobenzylguanidine therapy in patients with refractory pheochromocytoma and paraganglioma
por: Wakabayashi, Hiroshi, et al.
Publicado: (2019)

(123)I-Meta-Iodobenzylguanidine Single-Photon Emission Computerized Tomography/Computerized Tomography Scintigraphy in the Management of Neuroblastoma
por: Biassoni, Lorenzo, et al.
Publicado: (2021)

Co-existence of Functionally Different Vesicular Neurotransmitter Transporters
por: Münster-Wandowski, Agnieszka, et al.
Publicado: (2016)

Vesicular Glutamate Transporters (SLCA17 A6, 7, 8) Control Synaptic Phosphate Levels
por: Cheret, Cyril, et al.
Publicado: (2021)

Extracellular nucleotides inhibit growth of human oesophageal cancer cells via P2Y(2)-receptors
por: Maaser, K, et al.
Publicado: (2002)

Vimentin Mediates Uptake of C3 Exoenzyme
por: Rohrbeck, Astrid, et al.
Publicado: (2014)

Validation of 2-year (123)I-meta-iodobenzylguanidine-based cardiac mortality risk model in chronic heart failure
por: Nakajima, Kenichi, et al.
Publicado: (2018)

Diagnostic Use of Post-therapy (131)I-Meta-Iodobenzylguanidine Scintigraphy in Consolidation Therapy for Children with High-Risk Neuroblastoma
por: Wakabayashi, Hiroshi, et al.
Publicado: (2020)

Antiproliferative Properties of Type I and Type II Interferon
por: Bekisz, Joseph, et al.
Publicado: (2010)

An essential role of acetylcholine-glutamate synergy at habenular synapses in nicotine dependence
por: Frahm, Silke, et al.
Publicado: (2015)

Prediction of accumulation of 131I-labelled meta-iodobenzylguanidine in neuroblastoma cell lines by means of reverse transcription and polymerase chain reaction.
por: Mairs, R. J., et al.
Publicado: (1994)

Prediction of Long-term Cardiac Events by 123I-meta-Iodobenzylguanidine Imaging after acute Myocardial Infarction and Reperfusion Therapy
por: Nakamura, Manabu, et al.
Publicado: (2019)

Iodine-123-meta-iodobenzylguanidine Myocardial Scintigraphy in Isolated Autonomic Failure: Potential Red Flag for Future Multiple System Atrophy
por: Baschieri, Francesca, et al.
Publicado: (2017)

Selective serotonin reuptake inhibitors (SSRIs) prevent meta-iodobenzylguanidine (MIBG) uptake in platelets without affecting neuroblastoma tumor uptake
por: Blom, Thomas, et al.
Publicado: (2020)

Author Correction: A phase I clinical trial for [(131)I]meta-iodobenzylguanidine therapy in patients with refractory pheochromocytoma and paraganglioma
por: Wakabayashi, Hiroshi, et al.
Publicado: (2022)

Synaptophysin is involved in resetting of the mammalian circadian clock
por: Aramendy, Marie, et al.
Publicado: (2013)

Enhancement of Phosphorylation and Transport Activity of the Neuronal Glutamate Transporter Excitatory Amino Acid Transporter 3 by C3bot and a 26mer C3bot Peptide
por: Piepgras, Johannes, et al.
Publicado: (2022)

Predictors of antiproliferative effect of lanreotide autogel in advanced gastroenteropancreatic neuroendocrine neoplasms
por: Laskaratos, Faidon-Marios, et al.
Publicado: (2019)

Cost-Effectiveness Analysis of Iodine-123 Meta-Iodobenzylguanidine Imaging for Screening Heart Failure Patients Eligible for an Implantable Cardioverter Defibrillator in the USA
por: O’Day, Ken, et al.
Publicado: (2016)

CUDC-907, a dual PI3K/histone deacetylase inhibitor, increases meta-iodobenzylguanidine uptake ((123/131)I-mIBG) in vitro and in vivo: a promising candidate for advancing theranostics in neuroendocrine tumors
por: Grand-Guillaume, Joana, et al.
Publicado: (2023)

Antiproliferative effects of the arotinoid Ro 40-8757 in human gastrointestinal and pancreatic cancer cell lines: combinations with 5-fluorouracil and interferon-alpha.
por: Louvet, C., et al.
Publicado: (1996)

The Rho ADP-ribosylating C3 exoenzyme binds cells via an Arg–Gly–Asp motif
por: Rohrbeck, Astrid, et al.
Publicado: (2017)

The Higher Sensitivity of GABAergic Compared to Glutamatergic Neurons to Growth-Promoting C3bot Treatment Is Mediated by Vimentin
por: Adolf, Andrej, et al.
Publicado: (2020)

Impact of Diabetes on Cardiac Sympathetic Innervation in Patients With Heart Failure: A (123)I meta-iodobenzylguanidine ((123)I MIBG) scintigraphic study
por: Paolillo, Stefania, et al.
Publicado: (2013)

Thrombocytopenia after meta-iodobenzylguanidine (MIBG) therapy in neuroblastoma patients may be caused by selective MIBG uptake via the serotonin transporter located on megakaryocytes
por: Blom, Thomas, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8tukuja2nplh9btg4edmpl5rpp